MENU
FBT
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

FBT stock forecast, quote, news & analysis

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE ® Arca ® Biotechnology Index... Show more

Category: #Health
A.I.Advisor
published price charts
FBT
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for FBT with price predictions
Oct 21, 2026

FBT's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for FBT turned positive on October 20, 2026. Looking at past instances where FBT's MACD turned positive, the stock continued to rise in 45 of 50 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on FBT as a result. In 78 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.

FBT moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where FBT advanced for three days, in 296 of 341 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

FBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for FBT crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE ® Arca ® Biotechnology Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of 30 leading biotechnology companies.

Market Cap

The average market capitalization across the First Trust NYSE Arca Biotechnology Index Fund (FBT) ETF is 39.27B. The market cap for tickers in the group ranges from 1.96B to 236.98B. AMGN holds the highest valuation in this group at 236.98B. The lowest valued company is SRPT at 1.96B.

High and low price notable news

The average weekly price growth across all stocks in the First Trust NYSE Arca Biotechnology Index Fund (FBT) ETF was 10%. For the same ETF, the average monthly price growth was 18%, and the average quarterly price growth was 299%. ALKS experienced the highest price growth at 11%, while AXSM experienced the biggest fall at -4%.

Volume

The average weekly volume growth across all stocks in the First Trust NYSE Arca Biotechnology Index Fund (FBT) ETF was -10%. For the same stocks of the ETF, the average monthly volume growth was -13% and the average quarterly volume growth was -18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 72
P/E Growth Rating: 51
Price Growth Rating: 39
SMR Rating: 60
Profit Risk Rating: 62
Seasonality Score: 34 (-100 ... +100)
FBT's MACD Histogram just turned positive